ABSTRACT
BACKGROUND: Evaluation of feasibility, tolerance and efficiency for a new 3D interstitial HDR brachytherapy technique combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. PATIENTS AND METHODS: Between January 1997 and August 1998 we treated 35 patients with stage cT1-3 N0 M0 prostate cancer. Thirty-two patients with a follow-up of 12 to 28 months (median: 18 months) were evaluated. After ultrasound-guided transrectal implantation of 4 non-parallel needles, CT based 3D brachytherapy treatment planning ("Offenbach system") was performed. All patients received 4 fractions brachytherapy using a fractional dose of 5 or 7 Gy. Time between each fraction was 14 days. After brachytherapy 3D external irradiation followed up to 39.6 or 45.0 Gy. All patients received androgen deprivation, starting 2 to 19 months before brachytherapy, ending 3 months after 3D external radiotherapy. RESULTS: Posttreatment PSA levels dropped to < 1.5 ng/ml in 29/32 patients (91%). In 25 patients PSA levels were < 0.5 ng/ml, in 4 patients 0.5 to 1.5 ng/ml. In 2 patients we noted biochemical relapse. Transrectal implantation was very well tolerated. Grade 3 acute urinary toxicity occurred in 1 patient. We noted no Grade 2 or higher acute gastrointestinal toxicity. One patient developed a Grade 3 late urinary toxicity. No patient showed late gastrointestinal side effects. All 140 dose-volume histograms for 3D HDR brachytherapy were analyzed. CONCLUSIONS: The new 3D HDR brachytherapy technique, combined with 3D external irradiation and androgen deprivation, is a feasible, so far well-tolerated and effective treatment in the short-time follow-up of median 18 months.
Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Androgen Antagonists/therapeutic use , Brachytherapy/methods , Photons/therapeutic use , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Adenocarcinoma/blood , Adenocarcinoma/diagnosis , Aged , Biopsy , Brachytherapy/adverse effects , Combined Modality Therapy , Feasibility Studies , Follow-Up Studies , Humans , Male , Middle Aged , Particle Accelerators , Photons/adverse effects , Prostate/pathology , Prostate-Specific Antigen/blood , Prostate-Specific Antigen/radiation effects , Prostatic Neoplasms/blood , Prostatic Neoplasms/diagnosis , Radiotherapy Dosage , Time FactorsABSTRACT
We have developed a new interstitial HDR brachytherapy technique for the treatment of prostate cancer using CT based 3D planning after transrectal implantation of four non-parallel needles. CT based needle reconstruction, target definition, evaluation and documentation, including DVHs and 3D imaging, is a feasible, safe and well tolerated treatment concept.
Subject(s)
Adenocarcinoma/radiotherapy , Brachytherapy/methods , Prostatic Neoplasms/radiotherapy , Radiotherapy Planning, Computer-Assisted , Tomography, X-Ray Computed , Adenocarcinoma/diagnostic imaging , Adenocarcinoma/pathology , Brachytherapy/instrumentation , Cystoscopy , Dose Fractionation, Radiation , Feasibility Studies , Follow-Up Studies , Humans , Image Processing, Computer-Assisted , Male , Needles , Neoplasm Staging , Prostate/radiation effects , Prostatic Neoplasms/diagnostic imaging , Prostatic Neoplasms/pathology , Radiotherapy Dosage , Radiotherapy Planning, Computer-Assisted/methods , Rectum/radiation effects , Safety , Ultrasonography, Interventional , Urethra/radiation effectsABSTRACT
PURPOSE: To compare the efficacy of different calibration procedures for 192Ir high-dose-rate (HDR) brachytherapy sources and to determine their suitability in clinical practice. In addition the manufacturer's calibration is compared with our experimental measurements so that the accuracy of the source strength on the manufacturer certificate which is supplied with each new 192Ir source can be accessed. METHODS AND MATERIALS: We compared three types of calibration system: well-type chambers (HDR-1000 and SDS), cylindrical phantom, and plate phantom. The total number of measurements we obtained was 365. The number of sources used for the calibration procedure comparison was 20 and the number used for comparison with the manufacturer's calibration was 46. This study was made during the period 1989-1997. Also, Physikalisch-Technische Bundesanstalt (PTB) calibrated one of our sources using their PTB protocol so that the results could be compared with our own. RESULTS: The sensitivity of each system on scattering from the room walls was studied. It was found that different minimum lateral distances from the walls were required for the different systems tested: 15 cm and 25 cm for the well-type chambers, 75 cm for the cylindrical phantom, and 13 cm for the plate phantom. The minimum thickness required to reach phantom scattering saturation for the plate phantom setup is 24 cm. The influence of the applicator material used in the calibration setup was found to be 1.7% for the stainless steel dosimetry applicator compared to the plastic 5F applicator. The accuracy of source positioning within the applicator can lead to dosimetric errors of +/-1.2% for the radial distance of 8.0 cm used with both solid phantoms. The change in the response for both well-type chambers was only 0.1% for changes in the source position within +/-7.5 mm around the response peak. Good agreement was found between all dosimetry systems included in our study. Taking the HDR-1000 well-type chamber results as a reference, we observed percentage root mean square (RMS) values of 0.11% for the SDS well-type chamber, 0.44% for the cylindrical, and 0.60% for the plate phantom setup. A comparison of our results using the cylindrical phantom with those of the manufacturer showed a percentage RMS value of 3.3% with a percentage fractional error range of -13.0% to +6.0%. The comparison of our calibration results with those of PTB gave deviations less than 0.4% for all systems. CONCLUSIONS: Our results have shown that with careful use of all calibration system protocols an accurate determination of source strength can be obtained. However, the manufacturer's calibration is not accurate enough on its own, and it should be mandatory for clinics to always measure the source strength of newly delivered 192Ir brachytherapy sources. The influence of the applicator material, metal or plastic, should always be taken into account.
Subject(s)
Brachytherapy/instrumentation , Calibration/standards , Iridium Radioisotopes/therapeutic use , Phantoms, Imaging , Radiopharmaceuticals/therapeutic use , Physical Phenomena , Physics , Sensitivity and SpecificityABSTRACT
This paper describes the technique and preliminary results of high dose rate (HDR) interstitial brachytherapy for recurrent grade III and grade IV gliomas. Although in the initial treatment of malignant gliomas brachytherapy has been shown to give better results than external beam therapy, this has previously always been with low dose rate (LDR) brachytherapy. Stereotactic frames are used for interstitial LDR brachytherapy but a CT image-guided technique does not require such a frame. The survival rates for our initial 53 patients do not significantly differ from LDR results. However, using HDR there are several advantages, including a much shorter treatment time with HDR than LDR and better patient comfort. HDR also allows better individualized optimization of the treatment than LDR.
Subject(s)
Astrocytoma/radiotherapy , Brachytherapy/methods , Brain Neoplasms/radiotherapy , Adult , Aged , Astrocytoma/diagnostic imaging , Astrocytoma/mortality , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/mortality , Glioblastoma/diagnostic imaging , Glioblastoma/mortality , Glioblastoma/radiotherapy , Humans , Middle Aged , Radiotherapy Dosage , Survival Rate , Tomography, X-Ray ComputedABSTRACT
The benzofurane derivative benzbromarone (BBR) previously has led to liver tumor formation after long-term treatment of rats, but no indications of genotoxicity were detected. The present studies were designed to elucidate the mechanism(s) possibly involved in liver tumor formation by BBR. Female Wistar rats were used. Phenobarbital (PB) served as a positive control. (1) Short-term treatment (7 days) with daily doses of 2 to 100 mg/kg BBR led to adaptive responses in the liver, i.e., growth (increases in DNA, RNA, and protein) and induction of monooxygenases. These changes were also observed after feeding BBR for 8, 33, 77, and 102 weeks at doses of 2, 10, and 50 mg/kg/day but tended to weaken with time. Similar effects were obtained with PB fed at 2, 10, or 50 mg/kg/day. However, unlike PB, BBR did not enhance the expression of cytochrome P450-PB as demonstrated by immunostaining of histological liver sections. (2) BBR feeding for 102 weeks, but not for 77 weeks, produced some neoplastic liver nodules and at 50 mg/kg produced one hepatocellular carcinoma (HCC). Thus, BBR was tumorigenic in the present study, but was clearly weaker than PB which had induced liver nodules and HCCs at 77 weeks and even more markedly at 102 weeks. (3) To check for tumor-initiating activity 100 mg/kg BBR was given 14 hr after a two-thirds hepatectomy followed by promotion with PB (50 mg/kg) for 15 weeks. No phenotypically altered liver foci were detected. (4) To test for tumor-promoting activity rats received a single dose of N-nitrosomorpholine (250 mg/kg), and subsequently BBR or PB at doses of 2, 10, and 50 mg/kg/day. While PB markedly enhanced the development of neoplastic nodules and HCCs, BBR had only a weak enhancing effect on the induction of HCC, which was not dose related. gamma-glutamyl transpeptidase-positive foci dramatically increased in PB-treated animals, in contrast they showed no response after 2 and 10 mg/kg BBR and even decreased after 50 mg/kg BBR. (5) With PB changes in liver growth, monooxygenase activity, foci expansion, and tumor promotion all correlating with tumorigenesis in a quantitative manner, apparent no-observed-effect-levels are somewhat below 2 mg/kg (or 10 mg/kg for liver enlargement). (6) These studies suggest that BBR belongs to a group of nongenotoxic, growth-stimulating drugs with tumorigenic potential in rat liver. Its effects on the liver are different from those of PB, but seemed to resemble those of peroxisome proliferators, a hypothesis studied in the subsequent papers.
Subject(s)
Benzbromarone/toxicity , Microsomes, Liver/drug effects , Phenobarbital/toxicity , Animals , Carcinogenicity Tests , Cytochrome P-450 Enzyme System/metabolism , DNA/analysis , Enzyme Induction , Female , Immunohistochemistry , Microsomes, Liver/enzymology , Mixed Function Oxygenases/biosynthesis , Organ Size , Proteins/analysis , RNA/analysis , Rats , Rats, Inbred StrainsABSTRACT
During our radiooncologic experience, we have learned the problems caused by insufficient information on the patient and his tumor. Histologic data, stage and a drawing of the extension of the tumor are generally submitted to the radiotherapist. This study is intended to remind that some other factors are important for the radiooncologic decision about local and temporal dose distribution, such as tumor size, endometrial extension to the fundus, frequency of metastases and recurrences, different histology/grading, and performed surgical technique/radicality. The vital importance of these factors is explained. A new circular applicator is presented for routine afterloading irradiation with the selectron. The applicator has proved to be useful in practice. The problems of the afterloading technique as against the radium technique are indicated, especially with regard to the dose rate in point A.